TABLE 2

Plasma amino acid average concentrations (in μmol/l) in the postabsorptive state and after the euglycemic hyperinsulinemic clampa

BasalClamp
T2DM (n = 8)Control subjects (n = 10)T2DM (n = 8)Control subjects (n = 10)
Taurine126 ± 1261 ± 9137 ± 2047 ± 6
Asparagine9 ± 220 ± 47 ± 113 ± 2*
Threonine99 ± 7116 ± 663 ± 6*67 ± 5*
Serine87 ± 3107 ± 963 ± 4*65 ± 4*
Glycine154 ± 9173 ± 13143 ± 9134 ± 7
Alanine306 ± 16303 ± 25254 ± 9226 ± 11*
Citrulline35 ± 331 ± 224 ± 1*18 ± 1*
Valine250 ± 12227 ± 17173 ± 11*133 ± 12*
Methionine17 ± 120 ± 29 ± 1*14 ± 2*
Isoleucine70 ± 558 ± 430 ± 4*18 ± 2*
Leucine129 ± 5137 ± 1161 ± 5*69 ± 8*
Tyrosine49 ± 455 ± 429 ± 2*29 ± 2*
Phenylalanine49 ± 246 ± 234 ± 2*29 ± 2*
Ornitine62 ± 457 ± 440 ± 6*43 ± 4*
Lysine173 ± 5176 ± 10131 ± 7*122 ± 11*
Histidine68 ± 367 ± 458 ± 2*52 ± 4*
Arginine68 ± 391 ± 1648 ± 650 ± 7*
Total AA1,749 ± 261,726 ± 611,304 ± 57*1,117 ± 49*
BCAA447 ± 20423 ± 31264 ± 20*220 ± 20*
  • aBCAA = Branched-chain amino acids. Glutamine, glutamate, and proline were not determined.

  • *P < 0.05 or less vs. basal (by ANOVA, post hoc Tukey test).

  • P < 0.05.

  • P < 0.02 or less, type 2 diabetic vs. control subjects (by ANOVA, either interaction or group effect). T2DM, type 2 diabetic subjects.